Standard Treatment  No standard therapy is known to prolong survival. The usual approach is a trial of single-agent chemotherapy such as doxorubicin or 5-fluorouracil. Radiation to the tumor along with intravenous chemotherapy may relieve the pain of large liver masses, and radiation to painful bone or other metastases may also be appropriate.
 
Two-Year Survival  Less than 5 percent 

Investigational 
• Combination chemotherapy or new drugs may prove to be better treatment than those currently available.
  These would best be administered in a clinical trial, rather than using random combinations.
• Chemoembolization may improve symptoms even if there is metastatic disease.